Colorado Therapeutics
- Company typePrivate
- Founded2015
- HeadquartersLouisville, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Colorado Therapeutics firmographics
Firmographics- Name
- Colorado Therapeutics
- Legal name
- Colorado Therapeutics LLC
- Website
- https://co-therapeutics.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Colorado Therapeutics industry classification
Industry- Product category
- Soft Tissue Repair Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)
Keywords
Where Colorado Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Louisville
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Colorado Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Revenue model
- Biologic Tissue Implant Sales: Colorado Therapeutics generates revenue through the sale of its FDA-cleared XI-S+® xenogenic biologic tissue matrix for soft tissue repair applications including hernia repair. The product is sold directly to healthcare institutions and surgeons with pricing based on product size configurations.
- Licensing and Technology Partnerships: The company enters into licensing agreements to expand its product applications. In October 2016, Colorado Therapeutics entered a worldwide exclusive license agreement with Micro Interventional Devices to gain rights to the PolyCor™ compliant soft tissue anchoring technology for developing minimally invasive laparoscopic hernia anchoring devices.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | XI-S+® Product Sizes |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels3 records
Colorado Therapeutics product offering
Product offeringCore offering
Colorado Therapeutics manufactures and sells XI-S+®, a xenogenic (porcine pericardium) biologic tissue matrix with proprietary cross-linking treatment for soft tissue reinforcement and surgical repair of damaged or ruptured soft tissue membranes. The product is FDA 510(k) cleared, packaged dry and ready-for-use with no rehydration required, and is sold directly to hospitals and surgeons for hernia repair and other soft tissue applications.
Product overview
Colorado Therapeutics offers a single biologic tissue repair product, XI-S+®, which is a xenogenic porcine pericardium processed through the company's proprietary cross-linking technology. The product is FDA 510(k) cleared for implantation to reinforce soft tissue where weakness exists and for surgical repair of damaged or ruptured soft tissue membranes. XI-S+® is designed for hernia repair applications and is packaged in a dry, ready-to-use format requiring no preparation or rehydration.
Differentiator
Problem solved
Functional benefit
Products and services
- XI-S+® XI-S+® is a xenogenic (porcine pericardium) biologic tissue matrix processed through Colorado Therapeutics' proprietary cross-linked tissue treatment for soft tissue reinforcement and surgical repair of damaged or ruptured soft tissue membranes. It is FDA 510(k) cleared and packaged dry, ready-for-use, with no rehydration required, and is sold directly to hospitals and surgeons for hernia repair and other soft tissue applications. Available in multiple size configurations (XI0606-S+ 6x6cm, XI0508-S+ 5x8cm, XI0710-S+ 7x10cm, XI0808-S+ 8x8cm, XI0615-S+ 6x15cm).
Quantifiable outcome
- Highest burst strength/unit thickness among competitive products
- +4 more outcomes
Companies that use Colorado Therapeutics
Customer profileSegments2 records
Ideal customer profiles1 record
Colorado Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Colorado Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Micro Interventional Devices, Inc. (MID)coreColorado Therapeutics entered a worldwide exclusive license agreement with Micro Interventional Devices to gain rights to MID's proprietary PolyCor™ compliant soft tissue anchoring technology. The partnership aims to design and develop a minimally invasive laparoscopic hernia anchoring device for securing Colorado Therapeutics' FDA-cleared xenogenic biologic tissue matrix for hernia repair, with subsequent applications for venous valve implantation. Combining MID's anchor technology with Colorado Therapeutics' tissue matrix provides a unique solution for securing biologic tissue in minimally invasive procedures.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
Colorado Therapeutics competitors and assessment
Company assessmentBroad incumbents
- Smith & Nephew: Smith & Nephew's sports medicine and advanced wound management divisions include biologic grafts and surgical mesh products. Adjacent competitor in soft tissue repair with established global reach.
- Cook Medical: Cook Medical acquired Global Therapeutics — the prior company co-founded by Colorado Therapeutics CEO Joseph B. Horn — and is a major player in hernia repair and soft tissue reinforcement products. Directly comparable given overlapping biologic and surgical mesh portfolios and the founder lineage.
- LifeCell (Allergan/AbbVie): LifeCell's AlloDerm regenerative tissue matrix pioneered the human-derived biologic surgical mesh category. Directly comparable in biologic soft tissue matrix technology, though operating under a much larger aesthetic and regenerative medicine parent.
- BD (Bard): Becton Dickinson's Bard subsidiary is one of the dominant players in surgical mesh and hernia repair products. Major incumbent competitor with established hospital relationships and broad product portfolio.
- Ethicon (Johnson & Johnson MedTech): Ethicon is the market leader in hernia repair mesh and surgical soft tissue products. Largest direct competitor in the abdominal wall reconstruction and soft tissue reinforcement categories.
- Medtronic: Medtronic offers hernia repair and soft tissue reinforcement products as part of its broader surgical solutions portfolio. A major incumbent competitor in the hernia mesh market.
Direct peers
- Integra LifeSciences: Integra LifeSciences manufactures regenerative tissue technologies and surgical implants including dural repair, dermal matrices, and soft tissue reinforcement products. Highly comparable as a public peer in the biologic soft tissue matrix and regenerative implant space.
- TELA Bio: TELA Bio develops soft tissue reinforcement products for hernia and abdominal wall reconstruction using proprietary biologic and hybrid matrices. Direct competitor in the U.S. hernia and soft tissue repair market.
- RTI Surgical: RTI Surgical develops biologic implants and grafts for soft tissue, sports medicine, and surgical applications. Directly comparable as a pure-play biologic implant company.
Emerging players
- Aroa Biosurgery: Aroa Biosurgery develops soft tissue repair products from ovine forestomach matrix, including hernia and abdominal wall applications. Comparable emerging peer with biologic matrix technology targeting similar surgical soft tissue repair indications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Colorado Therapeutics social profiles
Digital presenceColorado Therapeutics compliance and trust
Trust signalCompliance2 records
Colorado Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Colorado Therapeutics leadership team
Management profileNumber of profiles
Profiles8 records
Colorado Therapeutics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Colorado Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Colorado Therapeutics
What does Colorado Therapeutics do?
Colorado Therapeutics manufactures and sells XI-S+®, a xenogenic (porcine pericardium) biologic tissue matrix with proprietary cross-linking treatment for soft tissue reinforcement and surgical repair of damaged or ruptured soft tissue membranes. The product is FDA 510(k) cleared, packaged dry and ready-for-use with no rehydration required, and is sold directly to hospitals and surgeons for hernia repair and other soft tissue applications.
Is Colorado Therapeutics a public or private company?
Colorado Therapeutics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Colorado Therapeutics founded?
Colorado Therapeutics was founded in 2015. It employs 11 to 50 people.
Where is Colorado Therapeutics based?
Colorado Therapeutics is headquartered in Louisville, United States, in the North America region.
How does Colorado Therapeutics make money?
Two revenue lines are on record. Biologic Tissue Implant Sales are the primary driver. The others are licensing and Technology Partnerships.
Who are Colorado Therapeutics's main competitors?
Broad incumbents on record are Smith & Nephew, Cook Medical, LifeCell (Allergan/AbbVie), BD (Bard), Ethicon (Johnson & Johnson MedTech) and Medtronic. Direct peers are Integra LifeSciences, TELA Bio and RTI Surgical. Aroa Biosurgery is listed as an emerging player.
Does Colorado Therapeutics have an API?
No public API is recorded for Colorado Therapeutics.
What industry is Colorado Therapeutics in?
Colorado Therapeutics's product category is Soft Tissue Repair Medical Devices. Its primary akta.pro industry code is HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts). Its NAICS code is 339113 and its SIC code is 3842.